Additionally, using a monoclonal antibody that only recognized ZIP7 when phosphorylated on S275 and S276, increased phospho-ZIP7 was confirmed in aggressive breast tumors [48], suggesting the potential for this antibody to be used as a biomarker in cancer. Here, SLC39A7 is linked to cancer.